JAZZ News and Press, Jazz Pharmaceuticals plc From 12/08/23

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer PR Newswire First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant...

NORTHAMPTON, MA / ACCESSWIRE / December 8, 2023 / Jazz Pharmaceuticals Originally Published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report Management Approach We aim to be an engaged corporate citizen globally and in our communities. We work through direct...

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting PR Newswire Data from nine abstracts to be presented, including real-world outcomes of Epidiolex ® ...

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings PR Newswire New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer...

NORTHAMPTON, MA / ACCESSWIRE / November 29, 2023 / Jazz Pharmaceuticals Originally Published in Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report Management Approach We seek to operate our business in an environmentally responsible way and are committed to meeti...

2023-11-27 13:44:41 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation Jazz Pharma: Playing The High Notes With Xywav Jazz Pharma enters coll...

2023-11-16 20:59:03 ET Summary Baupost Group's 13F portfolio value decreased from $5.61B to $5.21B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty Media Sirius XM, Veritiv, Alphabet, and Fidelity National Information Services accounting for ~56% of...

2023-11-14 16:00:00 ET Summary Avadel Pharmaceuticals reported strong Q3 earnings for Lumryz, exceeding consensus estimates and demonstrating successful market launch. Avadel's strategic market positioning and focus on high-volume prescribers contribute to its strong market positi...

2023-11-14 05:40:42 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation Jazz Pharma: Playing The High Notes With Xywav Jazz Pharmaceuticals Q3...

Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical ...